The Efficacy of Risperidone in treatment of Developmental stuttering in Persian adolescents aged 12-18 years old

Phase 2

Conditions: stuttering.
F98.5
Adult onset fluency disorder

Registration Number: IRCT20240410061463N1

Lead Sponsor: Babol University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 30

Inclusion Criteria

Age range from 12 to 18 years
Persian language
Be literate in reading and writing
Having a diagnosis of permanent developmental stuttering disorder based on the following criteria, the presence of both criteria is necessary: ??• Diagnosis of developmental stuttering by an experienced speech and language pathologist at the time of study • Obtaining a total score of 12 or higher in Riley's Stuttering Severity Test (SSI- 3)
Absence of any language or speech disorder other than stuttering in the past or present (will be checked by self-reporting by each participant)
Absence of any type of neurological, movement, vision, hearing, mental retardation, and autism spectrum disorders in the past or present, except for attention deficit hyperactivity disorder (ADHD) (with a clinical diagnosis by a psychiatrist)
Not taking drugs affecting cognitive function before or during the research (self-reporting will be checked by each participant)

Exclusion Criteria

The person's unwillingness to cooperate in every stage of the research

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
- The primary outcome of the study includes the improvement of stuttering severity using the SSI-3 measurement tool and the SR score by the individual at the beginning of the study, two weeks and six weeks after the start of treatment during a visit to the clinic. Timepoint: At the beginning of the study, two weeks and six weeks after the start of the treatment, it is during a visit to the clinic. Method of measurement: The primary outcome of the study includes the improvement of stuttering severity using the SSI-3 measurement tool and the SR score by the individual at the beginning of the study, two weeks and six weeks after the start of treatment during a visit to the clinic.

Secondary Outcome Measures

Name	Time	Method
- Secondary outcome is determined by measuring the side effects of drug use based on the AIMS questionnaire by a psychiatric assistant in two weeks and six weeks after the start of treatment. Timepoint: in two weeks and six weeks after the start of treatment. Method of measurement: is determined by measuring the side effects of drug use based on the AIMS questionnaire by a psychiatric assistant.